ROIV — Roivant Sciences Ltd. stock price, charts and financials

QT75Roivant Sciences Ltd.

Roivant Sciences Ltd. (NASDAQ: ROIV) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
39.77
-0.21-0.53%
OverviewShort InterestFilings
ROIVQT75Roivant Sciences Ltd.·NASDAQ
39.77-0.53%
Analyst
Down 0.5% — Stifel initiated coverage at Buy, price target $51.
Medium confidence
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
INSM-3.21%$120.00ALNY-2.42%$239.56INCY-1.81%$125.31BNTX-2.64%$96.06GMAB+0.61%$34.74UTHR-0.53%$494.63ONC-0.74%$350.84RVMD-3.04%$190.95
Snapshot
Index-P/E-EPS (ttm)-0.44Insider Own22.98%Shs Outstand722.41MPerf Week-2.57%
Market Cap28.73BForward P/E-EPS next Y-1.34Insider Trans-4.79%Shs Float577.47MPerf Month6.34%
Enterprise Value27.59BPEG0.87EPS next Q-0.41Inst Own-Short Float5.81%Perf Quarter26.54%
Income-267.19MP/S-EPS this Y-215.55%Inst Trans-Short Ratio5.47Perf Half Y43.06%
Sales7.53MP/B6.77EPS next Y3.49%ROA-5.02%Short Interest33.52MPerf YTD83.27%
Book/sh-P/C-EPS next 5Y-ROE-6.12%52W High42.50 -6.42%Perf Year160.27%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-27.14%52W Low14.50 174.28%Perf 3Y256.36%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-37.00% -19.73%Gross Margin81.21%Volatility3.39% 3.60%Perf 5Y299.30%
Dividend TTM-EV/Sales-EPS Y/Y TTM-83.33%Oper. Margin-18140.92%ATR (14)1.54Perf 10Y-
Dividend Ex-Date-Quick Ratio16.72Sales Y/Y TTM-72.41%Profit Margin-3534.88%RSI (14)60.17Recom2.07
Dividend Gr. 3/5Y-Current Ratio16.72EPS Q/Q-31.08%SMA205.25%Beta1.06Target Price46.75
Payout0.00%Debt/Eq0.03Sales Q/Q-50.00%SMA509.87%Rel Volume4.28Prev Close39.98
Employees721LT Debt/Eq0.02EarningsNov 09SMA20035.31%Avg Volume7.22MPrice39.77
IPO DateDec 08, 2020Option/ShortYes / YesEPS/Sales Surpr.-10.14% -29.89%Net Debt/EBITDA4.06Volume30,882,788Change-0.53%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-16-26InitiatedStifelBuy$51
Sep-09-26ReiteratedUBS$55
Sep-09-26ReiteratedGuggenheimBuy$36 → $46
Sep-08-26ReiteratedJefferiesBuy$30 → $52
Sep-08-26ReiteratedHC Wainwright & Co.Buy$41 → $47
Aug-07-26ReiteratedHC Wainwright & Co.Buy$34 → $41
May-26-26ReiteratedGuggenheimBuy$30 → $36
May-21-26ReiteratedCowen & Co.Outperform$38 → $41
May-21-26ReiteratedLeerink PartnersOutperform$32 → $42
Apr-16-26ReiteratedPiper SandlerOverweight$20 → $40
Latest News· Times ET
Sep-17-26
Sep-17-2603:51AM
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga
Sep-13-26
Sep-13-2603:30AM
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vantsseekingalpha.com
Sep-10-26
Sep-10-2603:13PM
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD - SlideshowSeekingAlpha
01:07PM
Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com
Sep-09-26
Sep-09-2611:57AM
Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcriptseekingalpha.com
Sep-08-26
Sep-08-2612:35PM
Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcriptseekingalpha.com
08:45AM
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcriptseekingalpha.com
05:17AM
Stock Futures Mixed to Start Holiday-Shortened Weekschaeffersresearch.com
05:12AM
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidatebenzinga.com
03:00AM
Roivant's experimental lung disease drug meets goals in mid-stage studyreuters.com
02:00AM
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Studyglobenewswire.com
02:00AM
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Studyglobenewswire.com
Sep-05-26
Sep-05-2609:00PM
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Callglobenewswire.com
09:00PM
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026globenewswire.com
Aug-30-26
Aug-30-2603:07PM
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis - SlideshowSeekingAlpha
Company

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
3/31/2026
FY 2024
3/31/2025
FY 2023
3/31/2024
FY 2022
3/31/2023
FY 2021
3/31/2022
FY 2020
3/31/2021
FY 2019
3/31/2020
Total Revenue8829—————
Cost of Goods Sold Incl. D&A111—————
Gross Profit5728—————
Selling, General and Administrative Excl. Other642610591—————
Research and Development731682550—————
Other Operating Expense-101—————
Operating Income-1,366-1,285-1,114—————
Interest Expense
000—————
Unusual Expense
————————
Non-Operating Income (Expense)1,0761,021432—————
Net Income Before Taxes-290-265-682—————
Income Taxes12413348—————
Consolidated Net Income-267-300-172—————
Net Income From Continuing Operations-415-398-730—————
Net Income-267-300-172—————
EPS (Recurring)-0.38-0.43-0.24—————
EPS (Basic, Before Extraordinaries)-0.38-0.43-0.24—————
EPS (Diluted)-0.44-0.43-0.24—————
EBITDA-281-261-668—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio3,584.272,402.98252.25—————
Gross Margin62.5087.5096.55—————
Operating Margin-17,075.00-16,062.50-3,841.38—————
Net Margin-3,337.50-3,750.00-593.10—————
Shares Outstanding721694725—————
Market Capitalization28,67419,2247,315—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$46.41$36.45$26.49$16.53$6.57● Close Price0.00M67.96M135.93M203.89M271.86MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Epperly Melissa B,DirectorSep 15 '26Sale39.744,938196,2309,900Sep 17
Fitzgerald MeghanDirectorSep 15 '26Sale39.745,112203,15236,108Sep 17
Fitzgerald MeghanDirectorSep 08 '26Option Exercise8.8020,000176,00062,963Sep 10
Fitzgerald MeghanDirectorSep 08 '26Sale39.9020,000798,00042,963Sep 10
Venker EricPresident & Immunovant CEOAug 28 '26Sale35.77200,0007,153,3931,599,154Sep 01
Venker EricPresident & Immunovant CEOAug 28 '26Option Exercise3.85200,000770,0001,799,154Sep 01
Sukhatme MayukhPresident & CIOAug 21 '26Sale36.48144,7565,280,69918,630,739Aug 21
Sukhatme MayukhPresident & CIOAug 21 '26Option Exercise3.85144,756557,31118,775,495Aug 21
Sukhatme MayukhPresident & CIOAug 20 '26Sale37.3017,519653,45918,630,739Aug 21
Sukhatme MayukhPresident & CIOAug 20 '26Option Exercise3.8517,51967,44818,648,258Aug 21
Sukhatme MayukhPresident & CIOAug 19 '26Sale37.17172,8996,426,65618,630,739Aug 21
Sukhatme MayukhPresident & CIOAug 19 '26Option Exercise3.85172,899665,66118,803,638Aug 21
Sukhatme MayukhPresident & CIOAug 18 '26Option Exercise3.85273,8841,054,45418,735,880Aug 18
Sukhatme MayukhPresident & CIOAug 18 '26Sale36.73136,9425,029,47018,630,739Aug 18
Sukhatme MayukhPresident & CIOAug 17 '26Option Exercise3.85284,7071,096,12218,915,446Aug 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.